Table 4.
Variable
|
Hazard ratio ratio
|
95%CI
|
B
|
Score
|
P
value (Cox regression)
|
Before treatment | |||||
BCLC stage | |||||
A | 1 | 0 | 0 | ||
B | 2.3 | 1.2-3.1 | 0.39 | 1 | 0.032 |
Irregular tumor margin | |||||
Absent | 1 | 0 | 0 | ||
Present | 1.9 | 0.7-3.3 | 0.42 | 1 | 0.028 |
Largest tumor size (cm) | |||||
< 5 | 1 | 0 | 0 | ||
≥ 5 | 1.7 | 0.6-2.9 | 0.47 | 1 | 0.017 |
Tumor number | |||||
Solitary | 1 | 0 | 0 | ||
Multiple | 2.1 | 1.1-3.1 | 0.33 | 1 | 0.021 |
Radiomics score | |||||
< 0.1 | 1 | 0 | 0 | ||
≥ 0.1 | 3.9 | 3.1-8.8 | 1.72 | 3 | < 0.001 |
The regression coefficients (B) in multivariate-Cox regression analysis were multiplied by 2 and rounded to calculate the radiomics-clinical score. The radiomics-clinical model used the median value (3.5) of total score (7) to stratify patients into high and low-risk group. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; BCLC: Barcelona Clinic Liver Cancer; B: B regression coefficient; CI: Confidence interval.